Artwork for podcast Pathfinders in Biopharma
MindMed: Rethinking brain health with psychedelic therapy
Episode 33 • 17th September 2025 • Pathfinders in Biopharma • RBC Capital Markets
00:00:00 00:11:58

Share Episode

Shownotes

Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and strong financial backing. CEO Rob Barrow outlines the company's ambitious goals and the path to potentially transforming mental healthcare at RBC's Global Healthcare Conference.

Follow

Links

Chapters

Video

More from YouTube